CAMBRIDGE, Mass.–(BUSINESS WIRE)–Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, today announced the appointment of Kate Haviland, Chief Business Officer of Blueprint Medicines, to its Board of Directors.
“Kate is an accomplished industry leader with deep business development and commercial strategy and planning expertise,” said Robert J. Gould, Ph.D., Fulcrum’s President and Chief Executive Officer. “Her experience guiding drug development strategy in the rare disease space will prove invaluable as we continue to build out our rare disease pipeline and accelerate our efforts to bring our lead program in FSHD into the clinic.”
Ms. Haviland joined Blueprint Medicines in 2016. In her role as Chief Business Officer at Blueprint Medicines, Kate is responsible for the business development, alliance management, corporate affairs, commercial strategy and operations, program management and information technology functions. Previously, she served as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals where she oversaw aspects of the product development and new product planning strategy for the company’s rare disease and oncology pipeline programs. Prior to joining Idera Pharmaceuticals, Kate was Head of Commercial Development at Sarepta Therapeutics, where she was responsible for product development and commercial planning and for cultivating relationships with key opinion leaders and patient advocacy groups. In addition, Kate previously served as Executive Director of Commercial Development at PTC Therapeutics and held corporate development and project management roles at Genzyme. She holds a B.A. from Wesleyan University with a double major in biochemistry/molecular biology and economics and an M.B.A. from Harvard Business School.
“I’m delighted to join the Board, as I share the Fulcrum team’s passion for improving the lives of patients and families affected by complex and severe genetic disorders,” said Haviland. “Throughout my career, I’ve sought to forge alliances between patients, clinicians and industry to cultivate meaningful advances in medicine. I look forward to sharing insights from these experiences and contributing to Fulcrum’s success as the company advances multiple programs towards clinical trials.”
About Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., was launched by Third Rock Ventures in 2016 and named a “Fierce 15” company later that year. For more information, please visit www.fulcrumtx.com.